BioDelivery Sciences International, Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Company Net Revenue to be in the range of $165 million to $167 million, compared to previous guidance of $162 million to $167 million.
BioDelivery Sciences International, Inc.
Equities
BDSI
US09060J1060
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+52.93% | 803B | |
+41.30% | 631B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.72% | 243B | |
+2.17% | 228B | |
+10.31% | 217B | |
+6.24% | 164B |